SeekingAlpha · Mar 6, 2026
RC
NASDAQ · RCKT
Rocket Pharmaceuticals, Inc.
Healthcare · Biotechnology
$2.51
Up+$0.10 (+3.98%)
Updated Nov 4, 2026, 11:50 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 372.83M
- P/E ratio
- -1.6
- Dividend yield
- 0.00%
- 52-week range
- $2.17 – $5.45
- Volume
- 1.29M
- Avg. volume
- 2.37M
Price performance · RCKT
RCKT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
RCKT closed at $2.51 after 21 trading sessions, up 1.21% for the selected period.
- Last close
- $2.51
- Period change
- +1.21%
- Period low
- $2.18
- Period high
- $2.63
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $2.49 | $2.635 | $2.42 | $2.51 | 1.29M |
| Nov 2, 2026 | $2.44 | $2.495 | $2.39 | $2.47 | 1.82M |
| Oct 30, 2026 | $2.50 | $2.57 | $2.37 | $2.44 | 1.54M |
| Oct 29, 2026 | $2.58 | $2.67 | $2.50 | $2.54 | 1.83M |
| Oct 28, 2026 | $2.42 | $2.605 | $2.372 | $2.58 | 1.42M |
| Oct 27, 2026 | $2.29 | $2.52 | $2.25 | $2.45 | 2.05M |
| Oct 26, 2026 | $2.29 | $2.291 | $2.22 | $2.28 | 1.51M |
| Oct 23, 2026 | $2.27 | $2.29 | $2.17 | $2.29 | 1.6M |
| Oct 22, 2026 | $2.20 | $2.34 | $2.18 | $2.31 | 2.16M |
| Oct 21, 2026 | $2.34 | $2.385 | $2.17 | $2.20 | 2.02M |
| Oct 20, 2026 | $2.24 | $2.37 | $2.20 | $2.34 | 1.89M |
| Oct 19, 2026 | $2.18 | $2.29 | $2.165 | $2.24 | 1.85M |
| Oct 16, 2026 | $2.36 | $2.36 | $2.17 | $2.18 | 1.97M |
| Oct 15, 2026 | $2.22 | $2.395 | $2.2068 | $2.36 | 1.88M |
| Oct 14, 2026 | $2.26 | $2.295 | $2.18 | $2.21 | 2.01M |
| Oct 13, 2026 | $2.47 | $2.55 | $2.26 | $2.30 | 3.89M |
| Oct 12, 2026 | $2.54 | $2.595 | $2.46 | $2.48 | 2.3M |
| Oct 9, 2026 | $2.59 | $2.6883 | $2.54 | $2.56 | 3.37M |
| Oct 8, 2026 | $2.78 | $2.78 | $2.52 | $2.63 | 3.46M |
| Oct 7, 2026 | $2.45 | $2.64 | $2.42 | $2.535 | 2.81M |
| Oct 6, 2026 | $2.61 | $2.62 | $2.46 | $2.48 | 1.79M |
Latest RCKT news
The latest Smart Investors Daily articles mentioning RCKT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RCKT research
Overview
Company profile and research snapshot.
Company profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | Goldman Sachs | Neutral | — |
| Oct 7, 2026 | Leerink Partners | Market Perform | — |
| Oct 7, 2026 | Wedbush | Outperform | — |
| Oct 7, 2026 | Chardan Capital | Buy | — |
| Sep 16, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 2, 2026
Goldman Sachs Maintains Sell on Rocket Pharmaceuticals, Raises Price Target to $3
Goldman Sachs analyst Richard Law maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Sell and raises the price target from $2 to $3.
Benzinga · Feb 27, 2026
Rocket Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS results. Also, Cantor Fitzgerald raised its price target on the stock from $8 to $10.
Benzinga · Feb 27, 2026
Cantor Fitzgerald Maintains Overweight on Rocket Pharmaceuticals, Raises Price Target to $10
Cantor Fitzgerald analyst Josh Schimmer maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and raises the price target from $8 to $10.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
